Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Ni,Xuefeng; Wu,Ping; Wu,Jun; Ji,Mei; Tian,Bo; Jiang,Zhenxing; Sun,Yue; Xing,Xiaoxiao; Jiang,Jingting; Wu,Changping

doi:10.3892/ol.2017.6342

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Authors:
- Xuefeng Ni
- Ping Wu
- Jun Wu
- Mei Ji
- Bo Tian
- Zhenxing Jiang
- Yue Sun
- Xiaoxiao Xing
- Jingting Jiang
- Changping Wu
View Affiliations

Affiliations: Department of Oncology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Pharmacology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Pathology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Radiology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Ultrasonography, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6342
Pages: 1691-1696

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study describes the use of bidirectional chemotherapy in the treatment of patients with gastric cancer and peritoneal carcinomatosis (PC), using newly developed response criteria for the treatment of malignant ascites. In addition, the association between effusion response and survival was analyzed. Between June 2010 and May 2014, patients affected by malignant ascites secondary to unresectable PC of gastric origin were treated with a combination of systemic and loco‑regional chemotherapy. Cisplatin (75 mg/m2) at an inflow temperature of 43˚C was infused intraperitoneally, and docetaxel (75 mg/m2) was infused simultaneously via a peripheral vein, on day 1 every 3 weeks. The primary endpoint was overall survival rate, and the secondary endpoint was efficacy against malignant ascites using new response criteria. In total, 41 patients were enrolled, the majority of whom received 6 cycles of intraperitoneal chemotherapy in combination with hyperthermia. The majority of patients exhibited clinical regression of ascites and relief of associated symptoms. Malignant ascites disappeared [complete response (CR)] or decreased by 50% [partial response (PR)] in 73.2% of patients. No mortalities associated with the procedures occurred. The median survival time was 8.6 months, and the 1‑year survival rate was 24.4%. As these new response criteria for the treatment of malignant ascites were found to be feasible, bidirectional chemotherapy may be the preferred strategy for the treatment of gastric cancer with PC. The CR, PR and non‑PR groups showed significant differences in overall survival, indicating that decreased effusion was associated with improved patient survival.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y and Kaminishi M: Gastric cancer treatment in Japan: 2008 nnual report of the JGCA nationwide registry. Gastric Cancer. 14:301–316. 2011. View Article : Google Scholar : PubMed/NCBI
4	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
6	Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, et al: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer. 88:358–363. 2000. View Article : Google Scholar : PubMed/NCBI
7	McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB and Rambo TD: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 27:65–73. 2001. View Article : Google Scholar : PubMed/NCBI
8	Garofalo A, Valle M, Garcia J and Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 32:682–685. 2006. View Article : Google Scholar : PubMed/NCBI
9	Glockzin G, Ghali N, Lang SA, Agha A, Schlitt HJ and Piso P: Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy. Chirurg. 78(1100): 1102–1106, 1108-1110. 2007.(In German).
10	Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 25:3217–3223. 2007. View Article : Google Scholar : PubMed/NCBI
11	Dedrick RL, Myers CE, Bungay PM and DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62:1–11. 1978.PubMed/NCBI
12	Markman M: Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol. 4:277–283. 2003. View Article : Google Scholar : PubMed/NCBI
13	Detroz B, Laurent S, Honoré P, Blaffart F, Limet R and Meurisse M: Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis. Acta Chir Belg. 104:377–383. 2004.PubMed/NCBI
14	González-Moreno S, González-Bayón LA and Ortega-Pérez G: Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2:68–75. 2010. View Article : Google Scholar : PubMed/NCBI
15	Van der Speeten K, Stuart OA and Sugarbaker PH: Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 6:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yan TD, Cao CQ and Munkholm-Larsen S: A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2:109–116. 2010. View Article : Google Scholar : PubMed/NCBI
17	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
18	Tozzoli R, Basso SM, D'Aurizio F, Metus P and Lumachi F: Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review. Clin Biochem. 49:1227–1231. 2016. View Article : Google Scholar : PubMed/NCBI
19	Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M and Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 36:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
20	Yan TD, Black D, Savady R and Sugarbaker PH: Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 24:4011–4019. 2006. View Article : Google Scholar : PubMed/NCBI
21	Chua TC, Robertson G, Liauw W, Farrell R, Yan TD and Morris DL: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: Systematic review of current results. J Cancer Res Clin Oncol. 135:1637–1645. 2009. View Article : Google Scholar : PubMed/NCBI
22	Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F and Elias D: Association Française de Chirurgie: Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 17:2370–2377. 2010. View Article : Google Scholar : PubMed/NCBI
23	Kim JY and Bae HS: A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer. 4:27–33. 2001. View Article : Google Scholar : PubMed/NCBI
24	Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, François Y, Vignal J and Gilly FN: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 139:20–26. 2004. View Article : Google Scholar : PubMed/NCBI
25	Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
26	Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y and Msika S: Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: A single western center experience. Eur J Surg Oncol. 34:1246–1252. 2008. View Article : Google Scholar : PubMed/NCBI
27	Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, et al: Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 100:311–316. 2009. View Article : Google Scholar : PubMed/NCBI
28	Los G, van Vugt MJ and Pinedo HM: Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer. 69:235–241. 1994. View Article : Google Scholar : PubMed/NCBI
29	Yonemura Y: Hyperthermo-chemotherapy for treatment of peritoneal disseminationPeritoneal Dissemination. Yonemura Y: Kanazawa: Maeda Shoten; pp. 237–260. 1998
30	Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y and Fujimura T: Society for Study of Peritoneal Carcinomatosis in Gastric Cancer: Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 71:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI
31	Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G and Staib L: Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am. 12:865–872, xvi-xvii. 2003. View Article : Google Scholar : PubMed/NCBI
32	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
33	Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G and Miwa K: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 178:256–262. 1999. View Article : Google Scholar : PubMed/NCBI
34	Sugarbaker PH and Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology. 58:96–107. 2000. View Article : Google Scholar : PubMed/NCBI
35	Chu DZ, Lang NP, Thompson C, Osteen PK and Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 63:364–367. 1989. View Article : Google Scholar : PubMed/NCBI